<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564756</url>
  </required_header>
  <id_info>
    <org_study_id>AAA-001</org_study_id>
    <nct_id>NCT03564756</nct_id>
  </id_info>
  <brief_title>Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)</brief_title>
  <acronym>AAA</acronym>
  <official_title>Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fetal Medicine Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wright State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Five Rivers Health Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fetal Medicine Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A. Anemia is a common problem affecting pregnancy and can result in profound consequences to
      both the mother and the growing fetus. Current treatment usually includes administration of
      oral or IV iron, or blood transfusions. Vitamin C is known to affect iron metabolism and has
      been shown to improve outcomes when used in addition to iron, however, few studies have been
      performed in pregnancy. The primary aim of this study is to identify the effects of vitamin C
      on anemia in pregnancy. The Investigators propose a double-blind, randomized placebo
      controlled trial of 1000mg vitamin C supplementation in 200 low risk pregnancies with
      iron-deficiency anemia. All newly enrolled patients, who meet inclusion and exclusion
      criteria, will receive the standard of care evaluation and treatment for anemia in pregnancy.
      Additionally, patients will be randomized to receive either placebo or vitamin C and
      compliance monitored with a pill diary. Data will be analyzed by T tests and Mann-Whitney U
      test. If the data shows a positive statistical significance, vitamin C may be a useful
      supplement to iron in treating anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Anemia is the most common hematological abnormality during pregnancy and was found to
      affect 24.1% of pregnant women in a WHO study.2 The most common types of anemia affecting
      pregnancy are iron-deficiency and acute blood loss. Vitamin C, also known as ascorbic acid,
      has been well documented to play an active role in the absorption and metabolism of iron from
      the gut.6 Vitamin C has been used in studies to treat anemic non-pregnant women resulting in
      significant increases in hemoglobin levels. Similar effects have been found in multiple
      studies using vitamin C as adjunct treatment for hemodialysis patients with non-responsive
      anemia.10,12 Vitamin C has already been extensively studied in pregnant women for its effects
      on preeclampsia, preterm birth, neonatal morbidity and other outcomes, and found to have no
      adverse effects in doses as high as 1000mg daily or in combination with other medications.8
      After an extensive literature search, very few studies have been performed assessing the
      effect on hemoglobin levels after vitamin C supplementation. One study by Sharma et al.
      supplemented pregnant women with 500mg vitamin C and found a 18.04% increase in hemoglobin
      compared to 5.49% in the control.11 A Cochran Review of 29 studies did not discuss or
      evaluate the effects of vitamin C on anemia.8 Due to the minimal side-effect profile and
      potential benefits of successfully treating anemia, further research in the area is needed.

      V. SPECIFIC AIMS OR OBJECTIVES A. To perform a double-blinded, randomized placebo controlled
      trial of 1000mg vitamin c supplementation on iron-deficiency anemia in low-risk pregnancies.

      VI. SIGNIFICANCE TO PATIENT, INSTITUTION, PROFESSION, OR ALL A. Anemia has been associated
      with adverse maternal and fetal outcomes, to include, but not limited to low birth weight,
      preterm delivery, perinatal mortality and postpartum depression.1 Per ACOG guidelines, all
      pregnant women should be screened for anemia, evaluated for causes and provided supplemental
      iron. A study by Sharma et al has already demonstrated a significant increase in hemoglobin
      levels in pregnancy with 500mg vitamin C supplementation.11 Due to the paucity of research of
      vitamin C in pregnancy, further studies are needed to determine reproducibility.

      VII. METHODS A. The investigators plan to enroll 200 patients total, 100 per arm. Potential
      subjects will be screened by study personal from the new intakes for prenatal care in the
      Five Rivers Center for Women's Health. A complete blood count (CBC) is obtained as standard
      of care at the first prenatal visit. The CBC includes hemoglobin level, hematocrit, and red
      blood cell indices (i.e. MCV and MCH). Pregnant women in the first half of their pregnancy
      who are found to have a hematocrit level less than 33% (Caucasian and other races), and less
      than 31% (African American women), will be potentially eligible for enrollment. Women who are
      noted to be anemic per these thresholds will have iron studies (iron, transferrin, ferritin)
      and hemoglobin electrophoresis (if not already performed), as part of the standard of care
      for the evaluation of anemia during pregnancy.1 Inclusion criteria consists of gestational
      age at enrollment less than 20 0/7 weeks, singleton gestation, iron deficiency anemia defined
      as maternal serum ferritin levels less than 15 micrograms/dL, and planned delivery at Miami
      Valley Hospital. Exclusion criteria consist of vitamin C use &gt;150mg/day (typical prenatal
      vitamin contains 60mg Vitamin C), diabetes (gestational, types 1,2); chronic medical disease;
      known or discovered hemoglobinopathy (including heterozygous states); known metabolic disease
      that may contribute to impaired iron absorption (including a history of bariatric surgery,
      renal disease and an inability to tolerate oral iron); known fetal abnormalities;
      participation in another interventional trial; illicit drug or alcohol use. All
      risks/benefits will be reviewed and all questions answered prior to the patient being
      enrolled. Written informed consent will be obtained by a study investigator or qualified
      personnel. Gestational dating will be based upon the best obstetrical estimate.

      B. A compounding pharmacy will make 30,000 placebo capsules containing an inert substance
      (i.e. silica based cellulose), identical appearing to 30,000 capsules of 500mg vitamin C. The
      pharmacy will package 300 pills of either placebo or vitamin C into 200 boxes, labeled only
      with the project name and a number. A key containing the known substance of each box and
      number will be kept by the pharmacy until the end of the study. The boxes will be stored in a
      secured area of the principal investigators office. The boxes will be taken to Five Rivers
      Women's Health Clinic to be distributed to enrolled patients. Once enrolled, patients will be
      given a random box and instructed to take 1 pill twice daily. Patients will be instructed to
      record pill usage daily for compliance. The patient's name and assigned box number will be
      kept in a locked cabinet. At the end of the study, the two keys will be compared to determine
      who received placebo or vitamin C. Both groups will receive prescriptions for ferrous
      sulfate, 65mg taken once daily; docusate sodium to be taken as needed for constipation; and
      prenatal vitamins once daily. Patients will receive follow up labs as part of the standard of
      care for anemia, to include at 28 week, and at delivery. All data will be collected in an
      Excel spreadsheet, with patient identifiers removed. Data will be analyzed by applying basic
      T tests and the Mann-Whitney-U test to determine the changes in lab values of hemoglobin,
      hematocrit, iron, transferrin, ferritin between experimental and control before and after
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Parallel Group, Placebo Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum hemoglobin</measure>
    <time_frame>To be measured at 1st prenatal visit, 28 weeks', and at delivery</time_frame>
    <description>Change in serum hemoglobin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anemia in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Iron + Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron + Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>One iron tablet once a day plus a placebo tablet twice a day until delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>1000mg Vitamin C per day</description>
    <arm_group_label>Iron + Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age at enrollment less than 20 0/7 weeks,

          -  singleton gestation,

          -  iron deficiency anemia defined as maternal serum ferritin levels less than 15
             micrograms/dL, and

          -  planned delivery at Miami Valley Hospital.

        Exclusion Criteria:

          -  vitamin C use &gt;150mg/day (typical prenatal vitamin contains 60mg Vitamin C),

          -  diabetes (gestational, types 1,2); chronic medical disease;

          -  known or discovered hemoglobinopathy (including heterozygous states);

          -  known metabolic disease that may contribute to impaired iron absorption (including a
             history of bariatric surgery, renal disease and an inability to tolerate oral iron);

          -  known fetal abnormalities;

          -  participation in another interventional trial;

          -  illicit drug or alcohol use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David McKenna, MD</last_name>
    <phone>937-208-5696</phone>
    <email>dsmckenna@premierhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaye Snow</last_name>
    <phone>937-208-2411</phone>
    <email>eksnow@premierhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Five Rivers Health Centers</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David McKenna, MD</last_name>
      <phone>937-208-5696</phone>
      <email>dsmckenna@premierhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaye Snow</last_name>
      <phone>937-208-2411</phone>
      <email>eksnow@premierhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>David McKenna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zoe Gauthier, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keshia Torres-Shafer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 95: anemia in pregnancy. Obstet Gynecol. 2008 Jul;112(1):201-7. doi: 10.1097/AOG.0b013e3181809c0d. Erratum in: Obstet Gynecol. 2020 Jan;135(1):222.</citation>
    <PMID>18591330</PMID>
  </reference>
  <reference>
    <citation>McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993-2005. Public Health Nutr. 2009 Apr;12(4):444-54. doi: 10.1017/S1368980008002401. Epub 2008 May 23.</citation>
    <PMID>18498676</PMID>
  </reference>
  <reference>
    <citation>Abdel Moety GAF, Ali AM, Fouad R, Ramadan W, Belal DS, Haggag HM. Amino acid chelated iron versus an iron salt in the treatment of iron deficiency anemia with pregnancy: A randomized controlled study. Eur J Obstet Gynecol Reprod Biol. 2017 Mar;210:242-246. doi: 10.1016/j.ejogrb.2017.01.003. Epub 2017 Jan 3.</citation>
    <PMID>28073037</PMID>
  </reference>
  <reference>
    <citation>Hanieh S, Ha TT, Simpson JA, Braat S, Thuy TT, Tran TD, King J, Tuan T, Fisher J, Biggs BA. Effect of low-dose versus higher-dose antenatal iron supplementation on child health outcomes at 36 months of age in Viet Nam: longitudinal follow-up of a cluster randomised controlled trial. BMJ Glob Health. 2017 Sep 22;2(3):e000368. doi: 10.1136/bmjgh-2017-000368. eCollection 2017.</citation>
    <PMID>29018582</PMID>
  </reference>
  <reference>
    <citation>Joseph B, Ramesh N. Weekly dose of Iron-Folate Supplementation with Vitamin-C in the workplace can prevent anaemia in women employees. Pak J Med Sci. 2013 Jan;29(1):47-52. doi: 10.12669/pjms.291.3016.</citation>
    <PMID>24353506</PMID>
  </reference>
  <reference>
    <citation>Lane DJ, Richardson DR. The active role of vitamin C in mammalian iron metabolism: much more than just enhanced iron absorption! Free Radic Biol Med. 2014 Oct;75:69-83. doi: 10.1016/j.freeradbiomed.2014.07.007. Epub 2014 Jul 15. Review.</citation>
    <PMID>25048971</PMID>
  </reference>
  <reference>
    <citation>Rumbold A, Crowther CA. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004072. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD004072.</citation>
    <PMID>15846696</PMID>
  </reference>
  <reference>
    <citation>Pe√±a-Rosas JP, De-Regil LM, Gomez Malave H, Flores-Urrutia MC, Dowswell T. Intermittent oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015 Oct 19;(10):CD009997. doi: 10.1002/14651858.CD009997.pub2. Review.</citation>
    <PMID>26482110</PMID>
  </reference>
  <reference>
    <citation>Sedighi O, Makhlough A, Janbabai G, Neemi M. Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon. 2013 Sep;5(4):913-7. doi: 10.5812/numonthly.12038. Epub 2013 Jul 24.</citation>
    <PMID>24350091</PMID>
  </reference>
  <reference>
    <citation>Sultana T, DeVita MV, Michelis MF. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency. Int Urol Nephrol. 2016 Sep;48(9):1519-24. doi: 10.1007/s11255-016-1309-9. Epub 2016 May 11.</citation>
    <PMID>27170339</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fetal Medicine Foundation</investigator_affiliation>
    <investigator_full_name>David S. McKenna</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Iron</keyword>
  <keyword>Vitamin C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be used by the study team to test the study hypothesis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

